ALK B ALK-ABELLO A/S

Major shareholder announcement

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, ALK (ALKB:DC / OMX: ALK B) hereby announces that Arbejdsmarkedets Tillægspension (“ATP”) (The Danish Supplementary Labour Market Pension) has informed ALK that ATP has reduced its ownership in ALK to below 5% of the share capital (previously 5.0%). The notification (in Danish) from ATP is attached to this company release.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. ALK manufactures and markets allergy immunotherapy (‘AIT’) treatments, acute anaphylaxis treatments, and other products and services for doctors and people with allergy. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at .

Attachment



EN
19/12/2025

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
02/23/26 February 23, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Ordinær generalforsamling i ALK-Abelló A/S den 16. marts 2026

Ordinær generalforsamling i ALK-Abelló A/S den 16. marts 2026 Ordinær generalforsamling i ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) finder sted mandag den 16. marts 2026 kl. 16.00 hos ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm i henhold til vedhæftede indkaldelse med bestyrelsens fuldstændige forslag, som fremsættes på generalforsamlingen. ALK-Abelló A/S For yderligere oplysninger kontakt venligst:Investor Relations: Per Plotnikof, tlf. 4574 7527, mobil 2261 2525Presse: Maiken Riise Andersen, tlf. 5054 1434 Om ALKALK er en global, specialiseret medicinalvirksomhed med fok...

February 20, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Annual General Meeting in ALK-Abelló A/S on 16 March 2026

Annual General Meeting in ALK-Abelló A/S on 16 March 2026 The Annual General Meeting of ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) will take place on Monday, 16 March 2026 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached. ALK-Abelló A/S For further information, contact: Investor Relations: Per Plotnikof, tel. , mobile Media: Maiken Riise Andersen, tel. About ALKALK is a global specialty pharmaceutical company focused on allergy. ALK's activiti...

February 20, 2026 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
02/20/26 February 20, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Henriette Mersebach fratræder som forskningsdirektør i ALK

Henriette Mersebach fratræder som forskningsdirektør i ALK ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) har i dag meddelt, at Henriette Mersebach fratræder som Executive Vice President, Research and Development, og som medlem af direktionen med virkning fra 23. februar 2026. Det er aftalt, at hun bistår med overlevering efter behov. Efter gensidig aftale har den administrerende direktør, bestyrelsen og Henriette Mersebach aftalt, at nu er det rette tidspunkt at udpege en ny forskningsdirektør med en anden profil for at styrke ALK’s innovationsindsats under Allergy+-strategien. Formålet er at b...

February 20, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch